Quest Diagnostics Incorporated (DGX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $28.56B
Last updated: Nov 17, 2026 at 11:03 AM ET
Quest Diagnostics Incorporated (DGX) P/E Ratio & Valuation History
Quest Diagnostics (DGX) trades at 23.8x trailing earnings and 2.4x sales. Its P/E of 23.8x is above its 5-year median of 16.2x. Its forward P/E is 21.5x. The median P/E across 11 similar companies is 28.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 10.7% higher over the next year. Its free cash flow yield is 4.8%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 23.8x |
| Forward P/E | 21.5x |
| Price to sales | 2.4x |
| Price to book | 3.8x |
| EV/EBITDA | 14.4x |
| Price to FCF | 21.0x |
| EV/FCF | 24.4x |
| PEG | 1.7 |
| FCF yield | 4.8% |
Historical Medians
Against its 10-year medians, its P/E is 44.2% above 16.5x, its P/S is 33.3% above 1.8x and its P/B is 46.2% above 2.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 23.8x | 16.2x | 16.5x |
| P/S | 2.4x | 1.7x | 1.8x |
| P/B | 3.8x | 2.6x | 2.6x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 10.7x in 2020 to 17.9x in 2016.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $173.53 | 17.6x | 1.8x | 2.7x |
| 2024 | $150.86 | 16.9x | 1.7x | 2.5x |
| 2023 | $137.88 | 15.8x | 1.7x | 2.5x |
| 2022 | $156.44 | 15.8x | 1.8x | 3.1x |
| 2021 | $173.01 | 12.2x | 2.0x | 3.4x |
| 2020 | $119.17 | 10.7x | 1.7x | 2.4x |
| 2019 | $106.79 | 16.3x | 1.9x | 2.6x |
| 2018 | $83.27 | 13.2x | 1.5x | 2.2x |
| 2017 | $98.49 | 17.4x | 1.8x | 2.8x |
| 2016 | $91.90 | 17.9x | 1.8x | 2.8x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DGX
What is DGX's forward P/E ratio?
Quest Diagnostics has a forward P/E ratio of 21.5x.
Is DGX stock overvalued?
GNG's valuation label for DGX is Fairly valued. Its P/E of 23.8x compares with a median of 28.5x across 11 similar companies.
What is DGX's price to sales ratio?
Quest Diagnostics has a price to sales ratio of 2.4x.
What is Quest Diagnostics's average P/E ratio over 5 years?
Quest Diagnostics's median P/E over the last 5 years is 16.2x, from 60 month-end values through Oct 2026.
What is DGX's PEG ratio?
Quest Diagnostics has a PEG ratio of 1.7.
DGX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts